$TTOO
T2 Biosystems, Inc. Stock $ttoo

$ttoo Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000156459022011526 Filed on March 23, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$6.980M	$28.06M	$7.790M
YoY Change	-10.4%	54.76%	153.83%
Cost Of Revenue	$5.362M	$20.70M	$7.480M
YoY Change	-28.32%	0.11%	107.2%
Gross Profit	$1.618M	$7.355M	$310.0K
YoY Change	421.94%	-388.43%	-157.41%
Gross Profit Margin	23.18%	26.21%	3.98%
Selling, General & Admin	$6.544M	$28.53M	$4.600M
YoY Change	42.26%	37.22%	-39.04%
% of Gross Profit	404.45%	387.86%	1483.87%
Research & Development	$5.353M	$21.80M	$4.040M
YoY Change	32.5%	28.85%	-5.59%
% of Gross Profit	330.84%	296.41%	1303.23%
Depreciation & Amortization	$270.0K	$1.300M	$390.0K
YoY Change	-30.77%	-23.98%	-23.53%
% of Gross Profit	16.69%	17.68%	125.81%
Operating Expenses	$11.90M	$50.33M	$8.630M
YoY Change	37.86%	33.46%	-27.02%
Operating Profit	-$10.28M	-$42.97M	-$8.320M
YoY Change	23.55%	3.91%	-32.72%
Interest Expense	-$1.860M	$6.586M	-$1.600M
YoY Change	16.25%	19.35%	-5.33%
% of Operating Profit
Other Income/Expense, Net	-$5.000K	-$6.268M	$10.00K
YoY Change	-150.0%	15.18%	-50.0%
Pretax Income	-$12.14M	-$49.24M	-$9.910M
YoY Change	22.54%	5.22%	-29.42%
Income Tax
% Of Pretax Income
Net Earnings	-$12.14M	-$49.24M	-$9.910M
YoY Change	22.54%	5.22%	-29.42%
Net Earnings / Revenue	-173.98%	-175.5%	-127.21%
Basic Earnings Per Share		-$15.50
Diluted Earnings Per Share	-$73.05K	-$310.0K	-$66.86K
COMMON SHARES
Basic Shares Outstanding		3.177M
Diluted Shares Outstanding		3.177M

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$32.24M	$32.24M	$42.19M
YoY Change	-23.58%	-23.58%	282.5%
Cash & Equivalents	$22.25M	$22.25M	$16.79M
Short-Term Investments	$9.996M	$9.996M	$25.40M
Other Short-Term Assets	$3.110M	$3.110M	$2.660M
YoY Change	16.92%	16.92%	84.72%
Inventory	$3.909M	$3.909M	$3.636M
Prepaid Expenses
Receivables	$5.134M	$5.134M	$5.099M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$44.39M	$44.39M	$53.58M
YoY Change	-17.15%	-17.14%	183.59%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.675M	$14.44M	$3.771M
YoY Change	23.97%	-2.49%	-35.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$0.00	$10.00M
YoY Change	-100.0%	-100.0%
Other Assets	$153.0K	$1.704M	$136.0K
YoY Change	12.5%	146.96%	-33.98%
Total Long-Term Assets	$16.15M	$16.15M	$25.49M
YoY Change	-36.67%	-36.69%	165.81%
TOTAL ASSETS
Total Short-Term Assets	$44.39M	$44.39M	$53.58M
Total Long-Term Assets	$16.15M	$16.15M	$25.49M
Total Assets	$60.54M	$60.54M	$79.08M
YoY Change	-23.44%	-23.45%	177.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.832M	$2.832M	$2.058M
YoY Change	37.61%	37.48%	-45.16%
Accrued Expenses	$8.338M	$8.338M	$7.512M
YoY Change	11.0%	11.03%	-32.97%
Deferred Revenue	$518.0K		$230.0K
YoY Change	125.22%		-19.3%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$11.69M	$11.69M	$9.800M
YoY Change	19.27%	19.27%	-83.82%
LONG-TERM LIABILITIES
Long-Term Debt	$47.79M	$47.79M	$45.24M
YoY Change	5.64%	5.64%
Other Long-Term Liabilities	$4.577M	$13.96M	$3.350M
YoY Change	36.63%	-8.85%	74.48%
Total Long-Term Liabilities	$4.577M	$61.75M	$3.350M
YoY Change	36.63%	1.97%	74.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.69M	$11.69M	$9.800M
Total Long-Term Liabilities	$4.577M	$61.75M	$3.350M
Total Liabilities	$16.27M	$73.44M	$13.15M
YoY Change	23.69%	4.4%	-78.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$472.2M		-$423.0M
YoY Change	11.64%		12.44%
Common Stock	$459.3M		$431.7M
YoY Change	6.4%		26.16%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$12.90M	-$12.90M	$8.726M
YoY Change
Total Liabilities & Shareholders Equity	$60.54M	$60.54M	$79.08M
YoY Change	-23.44%	-23.45%	177.6%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$12.14M	-$49.24M	-$9.910M
YoY Change	22.54%	5.22%	-29.42%
Depreciation, Depletion And Amortization	$270.0K	$1.300M	$390.0K
YoY Change	-30.77%	-23.98%	-23.53%
Cash From Operating Activities	-$9.842M	-$38.87M	-$8.750M
YoY Change	12.48%	-10.05%	-13.54%
INVESTING ACTIVITIES
Capital Expenditures	-$199.0K	$460.0K	-$370.0K
YoY Change	-46.22%	-42.79%	1750.0%
Acquisitions
YoY Change
Other Investing Activities	$10.00M	$25.25M	$6.750M
YoY Change	48.15%	-171.21%
Cash From Investing Activities	$9.801M	$24.79M	$6.370M
YoY Change	53.86%	-168.37%	-31950.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	239.0K	20.54M	110.0K
YoY Change	117.27%	-76.01%	-97.78%
NET CHANGE
Cash From Operating Activities	-9.842M	-38.87M	-8.750M
Cash From Investing Activities	9.801M	24.79M	6.370M
Cash From Financing Activities	239.0K	20.54M	110.0K
Net Change In Cash	198.0K	6.452M	-2.270M
YoY Change	-108.72%	5.24%	-56.18%
FREE CASH FLOW
Cash From Operating Activities	-$9.842M	-$38.87M	-$8.750M
Capital Expenditures	-$199.0K	$460.0K	-$370.0K
Free Cash Flow	-$9.643M	-$39.33M	-$8.380M
YoY Change	15.07%	-10.64%	-17.03%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17344000
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2020Q4	us-gaap	Inventory Work In Process And Raw Materials InventoryWorkInProcessAndRawMaterials	300000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1700000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14257000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3771000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3629000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11688000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18086671
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10533000
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y4M24D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y1M6D
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2021	dei	Auditor Name AuditorName	BDO USA, LLP
CY2021	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22245000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16793000
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	9996000
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	25396000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5134000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5099000
CY2021Q4	us-gaap	Inventory Net InventoryNet	3909000
CY2020Q4	us-gaap	Inventory Net InventoryNet	3636000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3110000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2660000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	44394000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	53584000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4675000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3771000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9766000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	11034000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1551000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	551000
CY2020Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	10002000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	153000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	136000
CY2021Q4	us-gaap	Assets Assets	60539000
CY2020Q4	us-gaap	Assets Assets	79078000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2832000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2058000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8338000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7512000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	518000
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	230000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9800000
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	47790000
CY2020Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	45235000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9359000
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	28000
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	424000
CY2020Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1010000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4577000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3350000
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	166000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	148000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	459151000
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	431544000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	9000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-472216000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-422975000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-12903000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	8726000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	60539000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	79078000
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	71031000
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	59486000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	112000
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	14000
CY2021	us-gaap	Interest Expense InterestExpense	6586000
CY2020	us-gaap	Interest Expense InterestExpense	5518000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6268000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5442000
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.39
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-4000
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	13000
CY2021	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	9000
CY2020	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	4000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-13000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	9000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-49254000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-46789000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-34005000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3913000
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	296000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	85311000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	9000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	8726000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7090000
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	567000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	19968000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-13000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-49241000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-12903000
CY2021	us-gaap	Profit Loss ProfitLoss	-49241000
CY2020	us-gaap	Profit Loss ProfitLoss	-46798000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1270000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1710000
CY2021	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	152000
CY2020	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	72000
CY2021	ttoo	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	1268000
CY2020	ttoo	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	1446000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	7090000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	3913000
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1010000
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1415000
CY2021	us-gaap	Debt Securities Available For Sale Gain Loss DebtSecuritiesAvailableForSaleGainLoss	14000
CY2020	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	2000
CY2020	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	523000
CY2020	us-gaap	Production Related Impairments Or Charges ProductionRelatedImpairmentsOrCharges	636000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	35000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2274000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	467000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1152000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1940000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-441000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	761000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1652000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	769000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	439000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-108000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	323000
CY2021	ttoo	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-1151000
CY2020	ttoo	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-2663000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38874000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-43215000
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	50711000
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	25251000
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	15250000
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	4000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	460000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	804000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	24791000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-36261000
CY2021	ttoo	Proceeds From Issuance Of Shares From Employee Stock Purchase Plan And Stock Option Exercises ProceedsFromIssuanceOfSharesFromEmployeeStockPurchasePlanAndStockOptionExercises	567000
CY2020	ttoo	Proceeds From Issuance Of Shares From Employee Stock Purchase Plan And Stock Option Exercises ProceedsFromIssuanceOfSharesFromEmployeeStockPurchasePlanAndStockOptionExercises	296000
CY2021	ttoo	Proceeds From Issuance Secondary Public Offering Net Of Offering Costs ProceedsFromIssuanceSecondaryPublicOfferingNetOfOfferingCosts	19968000
CY2020	ttoo	Proceeds From Issuance Secondary Public Offering Net Of Offering Costs ProceedsFromIssuanceSecondaryPublicOfferingNetOfOfferingCosts	85311000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20535000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6452000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6131000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11213000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	23796000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22245000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16793000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1551000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	551000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	23796000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17344000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	3814000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	3692000
CY2021	ttoo	Transfer Of T2 Owned Instruments And Components To From Inventory TransferOfT2OwnedInstrumentsAndComponentsToFromInventory	1667000
CY2020	ttoo	Transfer Of T2 Owned Instruments And Components To From Inventory TransferOfT2OwnedInstrumentsAndComponentsToFromInventory	478000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	9602000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	41000
CY2021	us-gaap	Nature Of Operations NatureOfOperations	<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of Business</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T2 Biosystems, Inc. and its subsidiary (the “Company,” “we,” or “T2”) have operations based in Lexington, Massachusetts. T2 Biosystems, Inc. was incorporated on April 27, 2006 as a Delaware corporation. The Company is an <span style="font-style:italic;">in vitro</span> diagnostics company that has developed an innovative and proprietary technology platform that offers a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company has developed a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. Our technology enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (“CFU/mL”). The Company’s initial development efforts target the detection of pathogens that cause sepsis, which is an area of significant unmet medical need in which existing therapies could be more effective with improved diagnostics. </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Going Concern</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2021, the Company had cash, cash equivalents, marketable securities and restricted cash of $33.8 million, an accumulated deficit of $472.2 million, stockholders’ deficit of $12.9 million, and has experienced cash outflows from operating activities over the past years. The future success of the Company is dependent on its ability to successfully commercialize its products, obtain regulatory clearance for and successfully launch its future product candidates, obtain additional capital and ultimately attain profitable operations. Historically, the Company has funded its operations primarily through its August 2014 initial public offering, its December 2015 public offering, its September 2016 private investment in public equity (“PIPE”) financing, its September 2017 public offering, its June 2018 public offering, its July 2019 establishment of an Equity Distribution Agreement and Equity Purchase Agreement (Note 7), its March 2021 establishment of an Equity Distribution Agreement (Note 7), private placements of redeemable convertible preferred stock and through debt financing arrangements. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.68%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to a number of risks similar to other early commercial stage life science companies, including, but not limited to commercially launching the Company’s products, development and market acceptance of the Company’s product candidates, development by its competitors of new technological innovations, protection of proprietary technology, and raising additional capital.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.68%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic has impacted and may continue to impact operations. The Company has established protocols for continued manufacturing, distribution and servicing of its products with safe social distancing and personal protective equipment measures and for remote work for certain employees not essential to on-site operations. To date these measures have been mostly successful but may not continue to function should the pandemic escalate and impact personnel. In 2020, the Company’s hospital customers restricted the sales team’s access to their facilities and as a result, the Company had significantly reduced sales and general and administrative staffing levels at the beginning of the COVID-19 pandemic to reduce expenses. The Company has since hired sales, marketing and medical and clinical affairs personnel. Although the Company did not see any material impact to accounts receivable during the period ended December 31, 2021, the Company’s exposure may increase if its customers continue to be adversely affected by the COVID-19 pandemic, including as a result of the spread of variants of the virus. Customers may reduce their purchases of products, depending on their needs and cash flow, which could negatively impact revenue. The Company has a significant development contract with BARDA and should BARDA reduce, cancel or not grant additional milestone projects, the Company’s ability to continue its future product development may be impacted. The ability of the Company’s shipping carriers to deliver products to customers may be disrupted. The Company has reviewed its suppliers and quantities of key materials and believes that it has sufficient stocks and alternate sources of critical materials including personal protective equipment should the supply chains become disrupted, although raw materials and plastics for the manufacturing of reagents and consumables are in high demand, and interruptions in supply are difficult to predict. As further described in Note 5, at the onset of the pandemic, the Company believed the pandemic’s impact on its sales would affect the recoverability of the value of T2-owned instruments and components. In early 2020, the COVID-19 pandemic also caused the Company to reassess its build plan and evaluate its inventories accordingly, which resulted in an additional charge to cost of product revenue for excess inventories.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.68%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since FDA authorization was obtained to market the T2Dx Instrument, T2Candida Panel, and T2Bacteria Panel, and EUA was issued for the T2SARS-CoV-2 Panel, the Company has incurred significant commercialization expenses related to product sales, marketing, manufacturing and distribution. The Company may seek to fund its operations through public equity, private equity or debt financings, as well as other sources. However, the Company may be unable to raise additional funds or enter into such other arrangements when needed, on favorable terms, or at all. The Company’s failure to raise capital or enter into such other arrangements if and when needed would have a negative impact on the Company’s business, results of operations, financial condition and the Company’s ability to develop and commercialize the T2Dx Instrument, T2Candida, T2Bacteria, T2SARS-CoV-2, and other product candidates.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Accounting Standards Codification (“ASC”) 205-40, <span style="font-style:italic;">Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern</span>, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued.</span></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes that its cash, cash equivalents, marketable securities and restricted cash of $33.8 million at December 31, 2021 will not be sufficient to fund its current operating plan at least one year from issuance of these financial statements unless additional funds are raised. Certain elements of our operating plan cannot be considered probable. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Term Loan Agreement with CRG Servicing LLC (“CRG”) (Note 6) has certain covenants which require the Company to achieve certain annual revenue targets, whereby the Company is required to pay double the amount of any shortfall as an acceleration of principal payments, and maintain a minimum cash balance of $5.0 million. In June 2021, the Company achieved the revenue target for the twenty-four month period ended December 31, 2021.There can be no assurances that it will continue to be in compliance with the cash covenant in future periods without additional funding. In February 2022, the CRG amended the Term Loan Agreement, extending the interest only period and maturity to December 30, 2023. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s stock has been trading under $1.00. <span style="color:#000000;">On November 5, 2021, the Company received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1). </span>Under Nasdaq rules, the Company has 180 days (May 4, 2022) to regain compliance by increasing the stock price to over $1.00. The Company plans to regain compliance by executing on its operating plans to organically drive the share price to compliance. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date that the financial statements are issued. Management's plans to alleviate the conditions that raise substantial doubt include raising additional funding, earning payments pursuant to the Company’s contract with BARDA, delaying certain research projects and capital expenditures and eliminating certain future operating expenses in order to fund operations at reduced levels for the Company to continue as a going concern for a period of 12 months from the date the financial statements are issued. Management has concluded the likelihood that its plan to successfully obtain sufficient funding from one or more of these sources or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, the Company has concluded that substantial doubt exists about the Company’s ability to continue as a going concern for a period of at least 12 months from the date of issuance of these consolidated financial statements.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p>
CY2021Q4	ttoo	Cash Cash Equivalents Marketable Securities And Restricted Cash CashCashEquivalentsMarketableSecuritiesAndRestrictedCash	33800000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-472200000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-12900000
CY2021Q4	ttoo	Cash Cash Equivalents Marketable Securities And Restricted Cash CashCashEquivalentsMarketableSecuritiesAndRestrictedCash	33800000
CY2021Q4	ttoo	Minimum Bid Price Of Common Stock MinimumBidPriceOfCommonStock	1.00
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company utilizes certain estimates in the determination of the accounts receivable allowance, the excess and obsolete inventory, the net realizable value of inventory, the fair value of its stock options, as well as restricted stock units that have market conditions, deferred tax valuation allowances, revenue recognition, expenses relating to research and development contracts, accrued expenses, the fair value of a derivative liability, the fair value of warrants and classification of the value of instrument raw material and work-in-process inventory between inventory and property and equipment. The Company bases its estimates on historical experience and other market‑specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from such estimates.</p>
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	500000
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	600000
CY2021	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	500000
CY2021Q4	ttoo	Number Of Financial Institutions NumberOfFinancialInstitutions	2
CY2020Q4	ttoo	Number Of Financial Institutions NumberOfFinancialInstitutions	2
CY2021	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0
CY2020	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	10000000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	4000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	9996000
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	35389000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	9000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	35398000
CY2021	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	100000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	698000
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	754000
CY2021	us-gaap	Lease Cost LeaseCost	3099000
CY2020	us-gaap	Lease Cost LeaseCost	2699000
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	10000000
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	9996000
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	25387000
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	25396000
CY2020Q4	ttoo	Available For Sale Securities Debt Maturities After One Through Two Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost	10002000
CY2020Q4	ttoo	Available For Sale Securities Debt Maturities After One Through Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue	10002000
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	10000000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	9996000
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	35389000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	35398000
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1591000
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1496000
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	953000
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1374000
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1365000
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	766000
CY2021Q4	us-gaap	Inventory Net InventoryNet	3909000
CY2020Q4	us-gaap	Inventory Net InventoryNet	3636000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	28058000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18130000
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	300000
CY2021	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Explanation RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation	The Company expects to recognize 97% of this amount as revenue within one year and the remainder within two years.
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.97
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2021Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0
CY2020Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0
CY2020	us-gaap	Production Related Impairments Or Charges ProductionRelatedImpairmentsOrCharges	600000
CY2020	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	500000
CY2021	us-gaap	Production Related Impairments Or Charges ProductionRelatedImpairmentsOrCharges	0
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2021	us-gaap	Guarantees Indemnifications And Warranties Policies GuaranteesIndemnificationsAndWarrantiesPolicies	<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Guarantees</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while each such officer or director is, or was, serving at the Company’s request in such capacity. The term of the indemnification is the officer’s or director’s lifetime. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors’ and officers’ liability insurance coverage that limits its exposure and enables the Company to recover a portion of any future amounts paid. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases office, laboratory and manufacturing space under noncancelable operating leases. The Company has standard indemnification arrangements under the leases that require it to indemnify the landlords against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation or nonperformance of any covenant or condition of the Company’s leases. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the ordinary course of business, the Company enters into indemnification agreements with certain suppliers and business partners where the Company has certain indemnification obligations limited to the costs, expenses, fines, suits, claims, demands, liabilities and actions directly resulting from the Company’s gross negligence or willful misconduct, and in certain instances, breaches, violations or nonperformance of covenants or conditions under the agreements. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021 and 2020, the Company had not experienced any material losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.</p>
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	20107000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	18028000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15432000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4675000
CY2021Q4	us-gaap	Inventory Work In Process And Raw Materials InventoryWorkInProcessAndRawMaterials	1400000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1300000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3687000
CY2021Q4	ttoo	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	1250000
CY2020Q4	ttoo	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	751000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	384000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	421000
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	974000
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	940000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1174000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1151000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	869000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	620000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8338000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7512000
CY2021Q4	ttoo	Long Term Debt Maturities Repayments Of Principal And Interest In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInNextTwelveMonths	49364000
CY2021Q4	ttoo	Debt Instrument Carrying Amount Including Paid In Kind Interest Before Unamortized Discount And Issuance Costs DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts	49364000
CY2021Q4	ttoo	Debt Instrument Unaccrued Paid In Kind Interest DebtInstrumentUnaccruedPaidInKindInterest	1287000
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	287000
CY2021Q4	us-gaap	Notes Payable NotesPayable	47790000
CY2021	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2022-12-30
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021	ttoo	Common Stock Number Of Votes Per Share CommonStockNumberOfVotesPerShare	1
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	166400892
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	148078974
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-49241000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-46798000
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	158861418
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	121331464
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.31
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.39
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	75749000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	84797000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	72404000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3029000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3345000
CY2021Q4	ttoo	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	2587000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	2401000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	1945000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.048
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.064
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.028
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.020
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.001
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.001
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.027
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.014
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.003
CY2021	ttoo	Effective Income Tax Rate Reconciliation Tax Credits Limitations On Credits And Net Operating Losses EffectiveIncomeTaxRateReconciliationTaxCreditsLimitationsOnCreditsAndNetOperatingLosses	-0.001
CY2020	ttoo	Effective Income Tax Rate Reconciliation Tax Credits Limitations On Credits And Net Operating Losses EffectiveIncomeTaxRateReconciliationTaxCreditsLimitationsOnCreditsAndNetOperatingLosses	0.001
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.252
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.270
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	73372000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	61551000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	2783000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1428000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3183000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3546000
CY2021Q4	ttoo	Deferred Tax Assets Start Up Expenditures DeferredTaxAssetsStartUpExpenditures	2392000
CY2020Q4	ttoo	Deferred Tax Assets Start Up Expenditures DeferredTaxAssetsStartUpExpenditures	2672000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3305000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3382000
CY2021Q4	ttoo	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	2791000
CY2020Q4	ttoo	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	3170000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	87826000
CY2020Q4	ttoo	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	2994000
CY2021Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	442000
CY2020Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	351000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	12400000
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	12600000
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.119
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.119
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2345000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2290000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2358000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2331000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1893000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	3957000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	15174000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4641000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	10533000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9766000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	11034000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9766000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	11034000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1174000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1151000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9359000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10533000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	10533000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	11684000
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	192000
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	163000
CY2021	dei	Auditor Firm AuditorFirmId	243

Files In Submission

Name	View Source	Status
0001564590-22-011526-index-headers.html	Edgar Link	pending
0001564590-22-011526-index.html	Edgar Link	pending
0001564590-22-011526.txt	Edgar Link	pending
0001564590-22-011526-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g0ayqa1bxsoc000001.jpg	Edgar Link	pending
gbyyvffvhyhy000001.jpg	Edgar Link	pending
ggkih3j1aghx000001.jpg	Edgar Link	pending
gjiivxsg20x5000001.jpg	Edgar Link	pending
gjjs15oi1heq000001.jpg	Edgar Link	pending
gzrmplpciwbk000001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ttoo-10k_20211231.htm	Edgar Link	pending
ttoo-10k_20211231_htm.xml	Edgar Link	completed
ttoo-20211231.xsd	Edgar Link	pending
ttoo-20211231_cal.xml	Edgar Link	unprocessable
ttoo-20211231_def.xml	Edgar Link	unprocessable
ttoo-20211231_lab.xml	Edgar Link	unprocessable
ttoo-20211231_pre.xml	Edgar Link	unprocessable
ttoo-ex102_597.htm	Edgar Link	pending
ttoo-ex1053_538.htm	Edgar Link	pending
ttoo-ex1054_548.htm	Edgar Link	pending
ttoo-ex1055_545.htm	Edgar Link	pending
ttoo-ex1056_542.htm	Edgar Link	pending
ttoo-ex1057_541.htm	Edgar Link	pending
ttoo-ex1058_544.htm	Edgar Link	pending
ttoo-ex1059_549.htm	Edgar Link	pending
ttoo-ex1060_539.htm	Edgar Link	pending
ttoo-ex211_7.htm	Edgar Link	pending
ttoo-ex231_11.htm	Edgar Link	pending
ttoo-ex311_14.htm	Edgar Link	pending
ttoo-ex312_6.htm	Edgar Link	pending
ttoo-ex321_12.htm	Edgar Link	pending
ttoo-ex322_13.htm	Edgar Link	pending
ttoo-ex44_16.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TTOO
T2 Biosystems, Inc. Stock $ttoo

2021 Q4 Form 10-K Financial Statement

#000156459022011526 Filed on March 23, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TTOO T2 Biosystems, Inc. Stock $ttoo

2021 Q4 Form 10-K Financial Statement

#000156459022011526 Filed on March 23, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TTOO
T2 Biosystems, Inc. Stock $ttoo